Longeviti Neuro Solutions

Longeviti operates at the intersection of medical devices, neurosurgery, and neurotechnology, with a focus on cranial reconstruction and access to postoperative ultrasound imaging. Its ClearFit® portfolio includes off-the-shelf and patient-specific implants, while InvisiShunt and InvisiLead extend its range of intracranial devices. The stated differentiator is the combination of cranial reconstruction with ultrasound-compatible designs that can support imaging through the skull after surgery. The company also announced ClearFit AI™, described as a Brain Ultrasound Interface, in 2026. This gives Longeviti a specialized position within a broader medical-device market rather than a clearly documented head-to-head position against named companies. Relevant competitive dimensions for assessing the company include implant design and customization, regulatory clearances, clinical evidence, surgeon adoption, and integration into neurosurgical workflows. Its Baltimore base and reported patent portfolio further characterize its profile as a focused device developer.

Longeviti was founded in 2016 and has built its growth around neurosurgical devices, including ClearFit® implants and InvisiShunt. The funding history shows a $9,589,743 Series B and a separate debt financing entry on June 28, 2019, followed by a $6 million Series C on September 23, 2020. Additional venture rounds between 2022 and early 2025 ranged from $750,000 to approximately $4.75 million. A notable financing inflection came on August 7, 2025, when Soleus Capital provided $10 million and Tim Scannell, a former Stryker President and COO, was named board chair. On June 8, 2026, a $1 million Maryland Department of Commerce grant brought the recorded cumulative funding total to $34,496,801. The June 2026 announcement of ClearFit AI™ signals an effort to extend the company’s ultrasound-related platform beyond implant design. Together, the funding and product announcements point to continued development and an expanding strategic profile.